Metastatic colonization of distant organs underpins the majority of human-cancer-related deaths, including deaths from head and neck squamous cell carcinoma (HNSCC). We report that miR-203, a miRNA that triggers differentiation in multilayered epithelia, inhibits multiple postextravasation events during HNSCC lung metastasis. Inducible reactivation of miR-203 in already established lung metastases reduces the overall metastatic burden. Using an integrated approach, we reveal that miR-203 inhibits metastasis independently of its effects on differentiation. In vivo genetic reconstitution experiments show that miR-203 inhibits lung metastasis by suppressing the prometastatic activities of three factors involved in cytoskeletal dynamics (LASP1), extracellular matrix remodeling (SPARC), and cell metabolism (NUAK1). Expression of miR-203 and its downstream effectors correlates with HNSCC overall survival outcomes, indicating the therapeutic potential of targeting this signaling axis.
Correspondence fiona.watt@kcl.ac.uk In Brief a microRNA that triggers differentiation in multilayered epithelia, as an inhibitor of lung metastasis in head and neck squamous cell carcinoma (HNSCC) cells. They show that miR-203 inhibits metastasis independently of its effects on differentiation. Rather, miR-203 suppresses the prometastatic activities of three factors involved in cytoskeletal dynamics (LASP1), extracellular matrix remodeling (SPARC), and cell metabolism (NUAK1). Expression of miR-203 and its downstream effectors correlates with survival in HNSCC patients.
INTRODUCTION
Adult stratified epithelia are maintained by a balance between stem cell self-renewal and differentiation (Arwert et al., 2012; Blanpain and Fuchs, 2006) . As emerging neoplastic drivers, stem cells and the factors that control their biology are of therapeutic relevance in carcinomas (Pardal et al., 2003) . For example, NOTCH1 and TP63 form a negative feedback loop in epidermal stem cells, with NOTCH1 promoting differentiation and TP63 inhibiting it (Nguyen et al., 2006) . Inactivation of these genes is associated with skin tumors in mice (Flores et al., 2005; Nicolas et al., 2003) and head and neck squamous cell carcinoma (HNSCC) in humans (Agrawal et al., 2011; Stransky et al., 2011) . Thus, disruption of the epithelial stem cell molecular circuitry can play a driving role in malignant transformation of the tissues they replenish.
HNSCC is the sixth most common cancer worldwide and has had a 5-year overall survival rate of only 50% for decades (Leemans et al., 2011) . Two-thirds of patients present with advanced, locally invasive disease that recurs despite mainstay surgery or chemo-and/or radiotherapy, thus creating a pressing need for novel avenues of therapeutic intervention (Argiris et al., 2008) .
Metastasis accounts for >90% of solid-cancer-related deaths (Valastyan and Weinberg, 2011) . Metastatic dissemination can occur early in the evolution of a tumor, followed by extended dormancy (Hü semann et al., 2008) . Indeed, up to 40% of carcinoma cases without clinical evidence of metastasis actually harbor disseminated tumor cells in the bone marrow (Pantel and Brakenhoff, 2004) . Thus, truly efficacious cancer therapeutics must target already established metastases rather than just inhibit tumor growth or dissemination (Valastyan and Weinberg, 2011) . miRNAs are small noncoding RNAs that posttranscriptionally repress target mRNAs important for tissue homeostasis and cancer (Lujambio and Lowe, 2012; Valastyan et al., 2009b) . Although our understanding of metastasis-relevant miRNAs has advanced rapidly in well-studied malignancies such as breast cancer (Valastyan et al., 2009a (Valastyan et al., , 2010 (Valastyan et al., , 2011 Yi et al., 2008) , we know little about whether and how miRNAs modulate metastasis in HNSCC. Therefore, we employed functional in vivo approaches to identify miR-203 as a potent negative regulator of HNSCC metastasis by targeting a panel of prometastatic effector proteins (Yi et al., 2008) .
RESULTS

A Screen of miRNAs in HNSCC Identifies miR-203 as a Metastasis Suppressor
To uncover endogenous miRNAs that reduce the lung metastatic potential of HNSCC, we employed the screening approach shown in Figure 1A . Using a panel of 17 primary, early-passage human HNSCC cell lines from surgically resected tumors, we assayed the expression of 15 miRNAs identified as coordinately deregulated in published expression profiles of HNSCC (see the Supplemental Experimental Procedures). We identified five downregulated miRNAs (miR-26b, miR-125b, miR-203, miR-218, and miR-373) and one upregulated miRNA (miR-15a) when we compared miRNA expression in HNSCC cells versus primary human keratinocytes ( Figure 1A ). miR-133a and miR133b were not detected in any lines.
To assess the function of the deregulated miRNAs in HNSCC, we generated two YFP-luciferase-expressing cell lines-SCC13 (established facial SCC; Rheinwald and Beckett, 1981) and SJG15 (primary lingual SCC; Goldie et al., 2012) -in which we knocked down miR-15a or stably overexpressed miR-26b, miR-125b, miR-203, miR-218, or miR-373 using lentiviral approaches ( Figure S1A) . No antiproliferative or cytotoxic effects were observed in vitro in adherent cultures ( Figure S1C) .
We explored the function of these miRNAs in an in vivo orthotopic tongue xenograft assay that recapitulates aspects of human HNSCC (Goldie et al., 2012) . SCC13 cells were injected into the lingual mucosa of nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-g chain null (NSG) mice ( Figure 1A ), and noninvasive, luciferase-based bioluminescent imaging was used to monitor disease progression (Kim et al., 2010; Tiffen et al., 2010) . Xenografting 10 5 miRNA expressing SCC13 cells revealed that overexpression of miR-203 and knockdown of miR-15a modestly reduced tumor burden after 26 days compared with control. The other miRNAs did not affect tumor burden (Figures 1B and S1D) .
To measure metastatic dissemination from the primary tumors, we imaged the lungs of tumor-bearing mice ex vivo at 26 days ( Figure 1C ). Overexpression of miR-26b and miR-218 enhanced metastatic dissemination, whereas the other four miRNAs had no significant effect ( Figure 1D ). Since the aim of the screen was to identify antimetastatic miRNAs, we did not analyze miR-26b and miR-218 further.
To examine metastatic colonization independently of primary tumor growth, we intravenously injected miRNA-expressing SCC13 and SJG15 cells into NSG mice ( Figure 1A ). Overexpression of miR-203 or knockdown of miR-15a suppressed metastasis in both cell lines, as determined by endpoint lung metastatic burden, ex vivo fluorescence microscopy, and histology . miR-125b and miR-373 were excluded from further analysis because their effects were not consistent between SCC13 and SJG15 cells. Since miR-15a is a tumor suppressor (Aqeilan et al., 2010) , we expressed miR15a in otherwise nonmetastatic, miR-15a low SCC25 cells (established lingual SCC; Rheinwald and Beckett, 1981 ; Figure S1B ). Overexpression of miR-15a did not enhance lung metastatic colonization by SCC25 cells ( Figure 1F) , so we did not analyze this miR further. With miR-203 presenting the most compelling case as a metastasis-suppressor gene, we explored its clinical relevance in a cohort of 219 HNSCC patients from The Cancer Genome Atlas (TCGA) (data available through the TCGA Data Portal; Figure 1G) . The 5-year survival rate of miR-203-low patients was 36%, compared with 70% for miR-203-high patients, independently of primary tumor size (T1/T2 versus T3/T4). Patients with miR-203-low tumors also exhibited significantly more lymph node-positive disease and lymphovascular invasion-two major prognostic factors for eventual distant metastasis. Hence, miR-203 is a prognostic indicator of overall survival and propensity for metastasis.
Using high-resolution copy-number data for 322 HNSCC patients from TCGA, we detected a copy-number alteration (CNA) harboring miR-203 that was focally deleted in 15% of cases ( Figure S2B ). This CNA included several genes that have been implicated in suppressing epithelial tumorigenesis and/or metastasis, such as DICER1 (Martello et al., 2010) and ELF5 (Chakrabarti et al., 2012) . The miR-203 locus was also deleted in cutaneous melanoma (34% of cases), lung adenocarcinoma (29% of cases), and glioblastoma multiforme (28% of cases) ( Figure S2C ). Therefore, deregulation of miR-203 in HNSCC (and potentially other tumor types) is due, at least in part, to focal CNAs that alter multiple tumor-and/or metastasis-suppressive pathways.
Effect of miR-203 Expression on Primary Tumor Growth
To examine miR-203 expression in vivo, we performed in situ hybridization in 28 cases of primary and/or metastatic skin SCCs with matched normal skin from the same patients, and three further cases of skin SCC (total of 11 patients; Table S1 ). Whereas miR-203 was strongly expressed in the suprabasal, differentiated layers of normal epidermis, confirming previous reports (Yi et al., 2008) , its expression was 35-fold lower in matched cutaneous SCCs (Figure 2A) .
We found that miR-203 significantly reduced both the average number and size of spheres formed by SCC13 in soft agar (Figure 2B and data not shown), consistent with the observation that when 10 5 cells were injected into the tongue, miR-203 reduced tumor growth ( Figure 1B) . To assess the impact on tumor growth in more detail, we xenografted 10 4 SCC13 cells expressing miR-203 or scrambled control hairpin (SCR) and monitored tumors for up to 50 days ( Figure 2C ). We confirmed miR-203 expression by in situ hybridization ( Figure S3B ). The reduction in tumor size upon expression of miR-203 was due to a lag in the initial rate of growth, and from week 2 onward the rate of tumor growth was comparable to that in control SCC13 cells (Figures 2C and S3A) . To investigate whether miR-203 affected the proportion of cells that were capable of initiating primary tumors, we performed a limiting dilution analysis (LDA) (Lapouge et al., 2012) in which 10 4 , 10 3 , 100, or 10 SCC13 SCR or miR-203 cells were injected into the tongue ( Figure 2D ). No difference in tumor incidence was observed between miR-203-and SCR-expressing cells ( Figure 2D ). There was, however, a lag in tumor growth phase at all seeding densities (Figures 2C and S1D; data not shown). We conclude that miR-203 overexpression does not affect the number of tumor-initiating cells or the overall tumor growth rate, but causes a delay before tumor growth becomes established, which results in a reduction in tumor size. This may explain the lack of a correlation between T stage and miR-203 expression in HNSCC patients, since, at least in xenografts, the effect on tumor size is more marked at early time points ( Figure 1G ).
miR-203 Expression Inhibits Lung Metastasis
We measured the circulating tumor DNA content by extracting whole peripheral blood 50 days after tongue xenografting (Figure 2C) and determined the levels of human AluJ or hLine1 repeat elements by quantitative PCR (qPCR) ( Figure 2E ). There was no difference in circulating tumor DNA content between (legend continued on next page) mice bearing miR-203 or control SCC13 primary tumors (Figures 2E and S3C) . However, ex vivo bioluminescence and fluorescence imaging of lungs showed that miR-203-expressing SCC13 cells founded smaller metastases than control cells (Figure 2F) . Therefore, miR-203 does not alter the ability of cells from the primary tumor to enter the circulation, but does hamper their capacity to expand following engraftment in the lungs. Consistent with these results, miR-203-expressing SCC13 and SJG15 cells exhibited a dose-dependent impairment in lung colonization following tail-vein injection ( Figure 2G ). Expression of miR-203 significantly prolonged the time required for SCC13 and SJG15 cells to reach input levels of lung bioluminescence, suggesting that miR-203 extended the dormancy phase of engrafted cells ( Figure 2G ), mirroring the phenotype observed in primary tumors ( Figure 2C ). Expression of miR-203 significantly increased survival time ( Figure 2H ) and reduced the endpoint lung metastatic burden ( Figure 2I ). This was confirmed by ex vivo fluorescence microscopy and anti-keratin-14 immunohistochemistry (IHC) of lungs (Figure 2J and S3E) . Whereas control SCC13 and SJG15 cells colonized the majority of the lung area, cells expressing miR-203 only generated small metastatic lesions or remained as clusters of individual cells (Figure S3F) . We confirmed that miR-203 expression was sustained in SCC13 lung metastases ( Figure S3G ). Taken together, these data suggest that miR-203 regulates the outgrowth of tumor cells once they have reached the lung.
We next asked whether endogenous miR-203 was necessary to prevent metastasis. For this purpose, we used SJG27 cells (primary lingual SCC), which express high levels of miR-203 and do not readily metastasize. Silencing miR-203 (miR-203 KD) in YFP-luciferase-labeled SJG27 cells did not impair proliferation in vitro ( Figures S3H and S3I ), but did enhance formation of clonogenic spheres in soft agar ( Figure 3A ). When injected into the circulation of mice, miR-203 KD SJG27 cells were significantly more proficient at forming lung metastases over 65 days compared with control cells ( Figure 3B ). Knockdown of miR-203 reduced the time to metastatic progression ( Figure 3C ) and enhanced the total lung metastatic burden ( Figure 3D ). Ex vivo fluorescence microscopy and anti-keratin-5 IHC showed that miR-203 KD cells generated more numerous and larger nodules than control cells ( Figure 3E ). Clusters of individual cells were visible in control, but not miR-203 KD, lungs, further suggesting a role for miR-203 in maintaining dormancy ( Figure S3J ).
We conclude, on the basis of miR-203 knockdown and overexpression, that miR-203 inhibits lung metastasis of HNSCC.
miR-203 Regulates Multiple Postextravasation Events and Inhibits Established Metastases
We next used a doxycycline (dox)-inducible system to temporally control miR-203 expression ( Figures 4A, 4B , and S4A). Dox-inducible miR-203 expression did not affect in vitro proliferation of adherent cells ( Figure S4B ), but reduced the anchorageindependent growth of SCC13 cells in soft agar ( Figure S4C) , consistent with the effect of constitutive expression ( Figure 2B ).
We activated miR-203 expression at defined time points following intravenous injection of SCC13 cells ( Figure 4B ). Expression of miR-203 was either never induced (mimicking cells lacking miR-203), induced before intravenous injection (day 0, phenocopying constitutive miR-203 expression), or induced 10 (dormancy phase of engrafted cells), 29 (establishment of micrometastases), or 56 days (macrometastatic colonization) after injection.
Animals injected with scrambled control cells that were never induced or induced from day 0, 10, 29, or 56 all had similar disease burdens, arguing against any effects of the dox-rich diet ( Figures 4C-4E and data not shown). An examination of RFP and GFP signals from lung metastases in each cohort of animals, as well as in situ hybridization for miR-203, confirmed doxdependent, sustained expression of miR-203 in vivo ( Figures  S4D-S4F and data not shown).
Activation of miR-203 for the duration of the experiment resulted in a 95% inhibition of endpoint lung metastatic burden ( Figures 4C and 4D ). Reexpression of miR-203 from 10 or 29 days was sufficient to block 80% of the endpoint lung metastatic burden ( Figures 4C and 4D ). Ex vivo fluorescence microscopy of lungs confirmed that reintroduction of miR-203 substantially reduced the number and size of lung metastases ( Figure 4E ). Although it was not statistically significant, animals in which miR-203 was induced for only the final 2 weeks of the experiment had 40% lower lung metastasis (Figures 4C and 4D) accompanied by a moderate reduction in lesion size and number ( Figure 4E ).
We next investigated whether miR-203 affects cancer cell extravasation across the lung vasculature in vivo ( Figure 4F ). Thirty hours after intravenous injection, multiphoton confocal imaging of individual GFP + tumor cells and tomato lectin-labeled blood vessels revealed that a similar proportion (90%) of control and miR-203-expressing SCC13 cells had successfully extravasated ( Figure 4G ). We conclude that miR-203 inhibits lung metastasis by inhibiting exit from dormancy, rather than by preventing migration from the primary tumor or entry into the lung.
miR-203 Induces Mutually Exclusive Transcriptomic Landscapes Characteristic of Keratinocyte Differentiation and Poorly Metastatic Cells
To probe the mechanisms by which miR-203 regulates metastasis, we performed genome-wide expression profiling and gene set enrichment analysis (GSEA) of miR-203-expressing SCC13 and SJG15 cells versus scrambled controls. Genome-(F) Time course of experimental lung metastasis by SCC25 cells overexpressing miR-15a or control vector for 119 days. Log 10 y axis, data are means ± SEM, n = 5 per group. (G) Kaplan-Meier plots for overall survival of 219 HNSCC patients from the TCGA cohort partitioned into miR-203-high (red, n = 28) and miR-203-low (blue, n = 191) cohorts based on miRNAseq read counts. The miR-203-high and -low patient cohorts were analyzed for the proportion of cases with lymph node disease (positive or negative), lymphovascular invasion (positive or negative), and primary tumor T-stage, which is a measure of tumour state and size. *p < 0.05; **p < 0.01; ***p < 0.001 (nonparametric Mann-Whitney test). For Kaplan-Meier plots, p values were calculated using a log rank Mantel-Cox test. For patient cohort comparisons, p values were calculated using Fisher's exact test. See also Figure S1 . wide expression changes elicited by miR-203 were negatively enriched for signatures of metastasis in primary human HNSCC arising in various anatomical locations within the aerodigestive tract (Cromer et al., 2004; O'Donnell et al., 2005; Rickman et al., 2008;  Figure 5A ). A similar negative enrichment between miR-203 and metastasis signatures was also found in (legend continued on next page) melanoma, breast, prostate, and endometrial tumors, all of which have a tendency to metastasize (data not shown). Together, these results suggest that miR-203 enforces a transcriptional landscape in human HNSCC cells that is restrictive for metastasis. GSEA also revealed that signatures of human keratinocyte differentiation were positively enriched in miR-203-expressing HNSCC cells (Kretz et al., 2012; Mulder et al., 2012; Sen et al., 2010; Figures 5A and 5B). However, there was no overlap between the core genes driving the metastasis and differentiation signatures ( Figure 5C ). This suggests that miR-203 uses mutually exclusive genetic strategies to prime the transcriptional landscape of HNSCC cells toward a poorly metastatic cell state and a differentiated state. In support of this prediction, there was no difference between control and miR-203-expressing SCC13 tongue tumors and lung metastases in expression of markers of undifferentiated keratinocytes, including keratin-5, keratin-14, a6-integrin, and p63. There was no difference in E-cadherin expression, and all tumors were negative for the epithelial-mesenchymal transition (EMT) markers N-cadherin and vimentin, with the exception of a few cells at the invasive edge (Figures S5A and S5B; cf. Taube et al., 2013) . There was also no difference in expression of the keratinocyte differentiation markers involucrin, keratin 10, and loricrin ( Figures S5C  and S5D ), or in markers of proliferation (Ki67 and phospho-histone H3), apoptosis (cleaved-caspase 3 positive), or vascular density ( Figures S6A-S6C ).
Hence, although miR-203 primed the transcriptional landscape of HNSCC cells toward a differentiated state, primary tumors and lung metastases did not exhibit alterations in differentiation status in vivo. These results suggest that the mechanism by which miR-203 controls metastasis is distinct from its prodifferentiation function in normal epidermis (Yi et al., 2008) .
miR-203 Directly Targets a Cohort of Genes Upregulated in HNSCC
To identify prometastatic miR-203 target genes, we used an integrated genomics, bioinformatics, and experimental approach ( Figure 5D ). We curated our microarray expression data for genes significantly downregulated by miR-203 and overlapped these hits (171 genes) with a list of 993 miR-203 predicted target genes from 11 publically available algorithms. To enrich for relevance in human HNSCC, we filtered the 13 hits through Oncomine (Rhodes et al., 2007) and the Human Protein Atlas (Uhlen et al., 2010) , and discovered four genes (LASP1, NUAK1, SPARC, and THBS2) that were upregulated in HNSCC specimens relative to normal mucosa. Furthermore, we observed tumor-specific upregulation of LASP1, NUAK1, SPARC, and THBS2 in an independent cohort of 24 oral SCC patients not contained in Oncomine ( Figure 5F ; Rhodes et al., 2007) . Genes associated with the actions of miR-203 in other cancers, such as BIRC5 (Saini et al., 2011) , SNAI2 (Ding et al., 2013) , P63 (Yi et al., 2008) , and c-Jun (Sonkoly et al., 2012), were not enriched in our samples.
To validate the results of our analysis, we showed that overexpression of miR-203 led to downregulation of LASP1, NUAK1, SPARC, and THBS2 in SCC13 and SJG15 cells ( Figure 5E ). Dox induction of miR-203 in SCC13 and SJG15 cells led to downregulation of LASP1, NUAK1, and SPARC, but not THBS2 ( Figure 5G ).
We focused on LASP1, NUAK1, and SPARC because of their involvement in metastasis-relevant processes such as cytoskeletal dynamics, energy metabolism, and extracellular matrix remodeling, respectively, and their previously described roles in cancer Minn et al., 2005; Traenka et al., 2010) . To determine whether or not LASP1, NUAK1, and SPARC are direct miR-203 targets, we cloned the 3 (Figure 5I) . Western blotting showed a miR-203-dependent reduction in LASP1, NUAK1, and SPARC protein levels ( Figure 5J ). Moreover, we found significant negative correlations between RNA sequencing (RNAseq) read counts of miR-203 and each of its three direct targets, but not TP63, across 225 HNSCC patients in TCGA ( Figure S2A ). We thus confirmed LASP1, NUAK1, and SPARC as direct target genes of miR-203 in human HNSCC.
LASP1, NUAK1, and SPARC Are Functionally Important Prometastatic Downstream Effectors of miR-203 that Are Prognostic of Overall Survival in HNSCC
To investigate the functional contribution(s) of LASP1, NUAK1, and SPARC to miR-203-induced inhibition of metastasis, we conducted genetic rescue experiments in vivo ( Figure 6A ). We engineered control and miR-203 expressing SCC13 cells to stably express all 16 possible combinations of miRNA-insensitive cDNAs (lacking 3 0 UTRs) encoding LASP1, NUAK1, and SPARC, and validated correct target gene reconstitution by western blotting ( Figure 6B ). The levels of exogenous protein expressed were sufficiently high that endogenous NUAK1 and SPARC ( Figure 5J ) could not be seen on the blots ( Figure 6B ).
All 16 SCC13 populations were intravenously injected into mice and lung metastasis was monitored for up to 88 days (Figures 6C, S6D , and S6E). Consistent with our earlier findings (Figure 2) , SCC13 cells expressing miR-203 together with three empty-vector controls (3xEV) did not colonize the lungs, whereas 3xEV SCC13 SCR cells generated numerous macrometastatic lesions ( Figure 6C ). Overexpression of SPARC or NUAK1 alone led to a small increase in metastasis of miR-203 cells, whereas overexpression of LASP1 alone caused a pronounced stimulation, which was comparable to overexpressing all three proteins ( Figures 6C, S6E , and S6E). Overexpression of LASP1 and/or SPARC, or combined expression of LASP1, SPARC, and NUAK1 did not enhance metastasis of SCR SCC13 cells ( Figures 6C-6F , S6D, and S6E). Unexpectedly, when NUAK1 was expressed alone or in combination with SPARC or LASP1, SCR SCC13 cells produced fewer metastases (Figures 6F and S6E) . Individual or combined reintroduction of NUAK1, SPARC, and/ or LASP1 was sufficient to bolster the lung metastatic colonization by SCC13 expressing miR-203 ( Figure 6C-6F) . NUAK1, SPARC, and LASP1 promoted exit from dormancy ( Figure 6D ) and overt pulmonary colonization, increasing the lung metastatic burden by 7-fold, 10-fold, and 53-fold, respectively (Figures 6E and 6F) . Thus, each miR-203 target promotes metastasis in the presence of miR-203, with the effect of LASP1 being most pronounced. In addition, knockdown of LASP1 reduced the clonogenic potential of SCC13 cells in vitro ( Figures S6F and S6G ), recreating the phenotype observed when miR-203 is expressed in the SCC13 cell line ( Figure 2B ).
The clinical relevance of the miR-203 target genes was confirmed in patient data. High expression of LASP1, NUAK1, and SPARC correlated with poor prognosis in both the TCGA cohort and a separate publically available HNSCC cohort (Figures 6G and 6H; Cromer et al., 2004) .
We conclude that miR-203 inhibits lung metastasis, not by triggering differentiation, but by directly targeting the prometastatic genes LASP1, SPARC, and NUAK1, which are prognostic factors in human HNSCC.
DISCUSSION
Our studies uncover miR-203 as a potent suppressor of key postextravasation events during lung metastasis. Reintroducing miR-203 into already established pulmonary nodules elicits their regression, suggesting the potential for therapeutic modalities aimed at activating miR-203 in cancer cells to treat metastatic HNSCC.
Recent evidence suggests that cancer cells hijack normal stem cell self-renewal signaling pathways to generate and propagate tumors in vivo (Reis et al., 2011) . If so, coaxing cancer cells to differentiate may inhibit tumor growth and metastasis. Although miR-203 promotes differentiation of normal epidermal stem cells (Jackson et al., 2013; Yi et al., 2008) , our study shows that it does not promote carcinoma differentiation in vivo. Instead, miR-203 controls HNSCC metastasis by targeting a network of prometastatic proteins, including LASP1, SPARC, and NUAK1. Thus, we propose that miR-203 undergoes a context-dependent functional switch from regulating normal differentiation to acting as a differentiation-independent roadblock to metastasis.
It is known that the genetic and epigenetic alterations sustained by host cells during malignant transformation alter the repertoire of mRNA species available for targeting by miRNAs (Lujambio and Lowe, 2012) . Thus, miRNAs can perform cellular-context-dependent functions driven by different cohorts of downstream effectors. For example, miR-126 inhibits breast cancer metastasis either by modulating the primary tumor microenvironment (Zhang et al., 2013) or by inhibiting lung metastatic colonization (Png et al., 2012) in mouse or human breast cancer models, respectively. As such, the rewiring of miR-203 function from regulating differentiation to inhibiting metastasis is likely to be explained by changes in target gene selection from differentiation-relevant proteins, such as TP63, to metastasis-promoting factors, such as LASP1, SPARC, and NUAK1. Our mechanistic studies identify LASP1, SPARC, and NUAK1 as important direct downstream effectors for miR-203-mediated inhibition of HNSCC metastasis. Prior studies have shown that these proteins promote cancer cell migration and invasion in vitro, promote tumor progression and/or metastasis in vivo, and correlate with poor overall survival in diverse carcinomas (Chang et al., 2012; Chin et al., 2005; Davis et al., 2008; Liu et al., 2012; Minn et al., 2005; Suzuki et al., 2004; Traenka et al., 2010; Viticchiè et al., 2011) . We speculate that LASP1, NUAK1, and SPARC promote postextravasation survival and/ or engraftment, shorten dormancy, and bolster overt pulmonary colonization by HNSCC cells.
Our data indicate that miR-203 is an upstream governor of several distinct cellular pathways that converge to enforce a poorly metastatic cell state, and highlight the importance of cellular context in determining the effects of a specific miRNA on metastasis. Indeed, miR-203 regulates tumor progression in breast and prostate cancer, but the targets of its action are very distinct among tissue types. In advanced metastatic prostate cancer, miR-203 targets BIRC5 (Saini et al., 2011) , whereas in breast cancer metastasis it targets SNAI2 (Ding et al., 2013) . This suggests that miR-203 not only functionally switches between tissue homeostasis and cancer progression, as shown here, but also switches targets depending on the cancer type.
In conclusion, our studies highlight miR-203 and its effectors as promising routes for therapeutic intervention in metastatic HNSCC. Unlike most anticancer agents and antimetastatic strategies currently in clinical trials (Valastyan and Weinberg, 2011), miR-203 can antagonize metastasis even after cancer cells have seeded the lung and formed clinically advanced nodules. In light of the development of targeted strategies to deliver nucleic acids into tumor cells (Davis et al., 2008) , we envision the potential value of using miR-203 mimetics to alleviate otherwise therapeutically intractable metastatic HNSCC.
EXPERIMENTAL PROCEDURES
Cell Lines SCC13, SCC25, SJG cell lines, and normal keratinocytes were cultured in FAD medium under standard conditions. Work with human material was either carried out in compliance with the UK Human Tissue Act (2004) and approved by the National Research Ethics Service (08/H0306/30) or according to the recommendations of the local ethics committee and the German Medical Council for diagnostic tissue used in research.
Animal Studies
Tongue xenografting and experimental lung metastasis experiments were performed as previously described (Goldie et al., 2012) . Animal studies were subject to Cancer Research UK and King's College London ethical review and performed in accordance with an approved UK Government Home Office license. A dox-rich diet (Harlan) was used to induce miR-203 expression in vivo. Bioluminescent imaging was conducted using a Xenogen IVIS 200 system (Perkin Elmer).
qRT-PCR, Microarrays, and GEO Data Sets RNA was isolated using a miRNeasy Mini Kit (QIAGEN), and qRT-PCR was performed using TaqMan probes (Life Technologies) and SYBR Green primers. Genome-wide expression analysis was carried out on Illumina Human HT12 version 4 arrays. Microarray data sets GSE31056 and GSE2379 were downloaded from NCBI GEO. TCGA data were downloaded from https://tcga-data.nci.nih.gov/tcga/ and http://www.broadinstitute.org/tcga/ home.
Statistical Analysis
An unpaired two-tailed Student's t test (in vitro experiments) or a nonparametric Mann-Whitney test (in vivo mouse experiments) was used for comparisons, with p < 0.05 considered significant. A log rank (Mantel-Cox) test was used to compare survival curves and compute hazard ratios, and Fisher's exact test used to compare human cohorts on the basis of clinical characteristics.
ACCESSION NUMBERS
The NCBI Gene Expression Omnibus accession number for the gene expression data reported in this paper is GSE47028. (C) Time course of experimental lung metastasis generated by control (SCR) SCC13 cells expressing 3xEV and miR-203 SCC13 cells expressing 3xEV, NUAK1, SPARC, or LASP1, or NUAK1, SPARC, and LASP1 together (N+S+L) over 88 days (n = 5 per group). Log 10 y axis; data are means ± SEM with n = 4-5 per group. Data were selected from the full set of combinations presented in Figure S6D . (D) Kaplan-Meier plots for time to progression of lung metastasis of control and miR-203 SCC13 cells expressing 3xEV, LASP1 alone, or all three target gene cDNAs; p values were calculated using the log rank Mantel-Cox test; n = 4-5 per group. (E) Lung metastasis formed by 3xEV, NUAK1, SPARC, or LASP1, or NUAK1, SPARC, and LASP1 together (N+S+L) of miR203 SCC13 cell lines and 3xEV in the SCR SCC13 cell line, analyzed at day 88. Whiskers indicate min/max and the horizontal bar is median, with n = 4-5 per group. Log 10 y axis. *p < 0.05 and **p < 0.01 were calculated using the nonparametric Mann-Whitney test in comparison with miR-203 3xEV. (F) Representative whole-mount ex vivo GFP fluorescence microscopy images of lung metastases formed by all 16 combinations of SCC13 cell lines at day 88. Scale bar represents 3 mm. (G) Kaplan-Meier plots for overall survival of 272 HNSCC patients from the TCGA cohort partitioned on the basis of LASP1, NUAK1, and SPARC RNAseq read counts; p values were calculated using the log rank Mantel-Cox test. (H) LASP1, NUAK1, and SPARC mRNA expression was used to partition the GSE2379 cohort of 34 HNSCC patients; p values were calculated using the log rank Mantel-Cox test. µm.
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*P < 0.05; **P < 0.01; ***P < 0.001 calculated using a non-parametric MannWhitney test (mouse experiments) or a two-tailed Student's t-test (qRT-PCR data). *P < 0.05; **P < 0.01; ***P < 0.001 calculated using a two-tailed Student's t-test for panels (d) and (h). *P < 0.05; **P < 0.01; ***P < 0.001 calculated using a two-tailed Student's t-test. Table S1 . Clinical information of patients from whom matched skin and SCCs were resected and used for miRNA in situ hybridization. Related to Figure 2 .
Supplemental Experimental Procedures
Cell Lines and Human Tissue
The human facial skin SCC line, SCC13, was obtained from ATCC. All cell lines were cultured at 37°C with 5% CO 2 in FAD medium (three parts DMEM medium, one part F12 medium and 10 -4 M adenine, supplemented with 10%
Fetal Bovine Serum Gold (PAA), 2 mM L-glutamine, 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, 10 -10 M cholera toxin, 10 ng/ml epidermal growth factor, 100 IU/l penicillin and 100 µg/l streptomycin (Gibco). HEK293T cells for lentiviral packaging were maintained in DMEM supplemented with 10% Fetal Bovine Serum, 100 IU/l penicillin and 100 µg/l streptomycin (Gibco). Cell lines passed mycoplasma testing.
For in vitro sphere forming assays, 1 ml of a 1% agar/FAD medium base layer was added to a 6-well culture plate (Corning) and 1,000 -3,000 cells (depending on assay) were suspended in 1 ml 0.8% agar/FAD medium and seeded on top the solidified base layer. The cells were cultured for 21 days, stained with 0.01% Crystal Violet and imaged using a Bio-Rad XR+. For in vitro doxycycline induction experiments, cells were grown in the presence of 1mg/ml doxycycline (filtered and diluted in PBS) for 3 days (Sigma).
Plasmid Construction
To generate miRNA-expression vectors, the human sequences encoding miR-15a, These plasmids were used as empty vector controls. NUAK1 cDNA was then inserted into LeGO-iCer2 and SPARC cDNA into LeGO-iC2 using standard Gateway cloning techniques (Invitrogen) and sequence verified. A pLOC empty vector was generated by excising the LASP1 cDNA, blunting with Klenow, and ligating ends (NEB).
To generate psiCheck2-3'UTR reporter plasmids, relevant 3'UTR sequences were obtained from Ensembl, PCR amplified from normal human keratinocyte genomic DNA, verified by gel electrophoresis and gel purified when required, and subsequently cloned into the XhoI and NotI sites of psiCheck2 (Promega). Mutant
UTRs were generated using a QuikChange XL Site-Directed Mutagenesis kit (Agilent) with the following differences: extension time (2.5min/kb), 3% DMSO, and 100ng input DNA. All plasmids were sequenced verified.
A retrovirus expressing a yellow fluorescent protein and codon-optimized firefly luciferase (YFP-Luc) fusion protein was a generous gift from Dr. Scott Lyons. 
Virus Production and Generation of Stable Cell
RNA Extraction and qRT-PCR Expression Analysis
We curated miRNA expression data from 12 previously published studies using either primary HNSCC samples or cell lines for miRNAs coordinately deregulated in at least 3 of 12 reports (49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60) The output list of 20 miRNAs was refined down to 15 miRNAs by excluding miRNAs with welldocumented roles in cancer at the time of study initiation (miR-21, miR-31, miR-155, and the let-7 family) (61) . miR-199b was removed from our candidate list given that the multiplexed primer pool used to assay miRNA expression did not feature a primer for this miRNA.
Total RNA was isolated using the miRNeasy Mini Kit (Qiagen) for both miRNA and mRNA expression analysis. For miRNA expression analysis, 500 ng input RNA was reverse transcribed using the TaqMan Megaplex Human Primer Pool 
Microarray Experiments and Gene Set Enrichment Analysis
Total RNA was isolated in technical duplicates from YFP-luciferase expressing SCC13 and SJG15 cells stably infected in biological duplicates with either miR-203 or scrambled control hairpin using a miRNeasy Mini Kit (Qiagen). RNA quality was analyzed using a Bioanalyzer 2100 (Agilent) and the RNA Nano chip.
Gene expression analysis was carried out on Illumina Human HT12 version 4
arrays. All data analyses were carried out on R using Bioconductor (62) packages.
Raw intensity data from the array scanner were processed using the BASH (63) and HULK algorithms as implemented in the beadarray package (64) . Log2 transformation and quantile normalization of the data were performed across all sample groups. Differential expression analysis was carried out using the limma package (65) . Differentially expressed genes were selected using a p-value cut-off of <0.05 after application of FDR correction for multiple testing applied globally to correct for multiple contrasts. Gene expression data has been deposited into NCBI GEO and is accessible under accession number GSE47028.
GSEA and Leading Edge Analysis was performed using GSEA v2.0 software (Broad Institute) (66) . Genes were ranked according to fold change from highest to lowest in miR-203 expressing SJG15 compared to control, or BMP2/7-treated primary human keratinocytes compared to control (33; GSE34558). The median value of probe sets present more than once was used and statistical significance assessed using 1000 random permutations of the gene set. An FDR q-value < 0.2 was considered significant. Gene sets were obtained from the MSigDB database v3.1 (September 2012 release) or from the published datasets indicated in the main text.
Other datasets used but not shown are the following: melanoma (67, 68, 69) , breast (70) , prostate cancer (71) , and endometroid endometrial tumors (72) .
Luciferase Reporter Assays
HEK293T cells were seeded in white-coated 96 well plates (Corning) at a density of 10,000 cells/well overnight. 10ng psiCheck2-3'UTR vector was co-transfected with 20nM miRNA mimic molecules (Dharmacon) using jetPRIME (Polyplus), and incubated for 48 hours. Cells were subsequently lysed and a Dual-Luciferase assay (Promega) was performed using a PHERAstar FS multi-mode microplate reader (BMG LabTech) and standard protocols. Normalized luminescent signal (i.e.
Renilla/Firefly ratio) in miRNA mimic transfected wells was compared to values from negative control miRNA transfected wells. For bioluminescent imaging, mice were injected intraperitoneally with 200 µL D-luciferin dissolved in PBS (15mg/ml), anaesthetized with isofluorane, and imaged using a Xenogen IVIS 200 system 10 min after injection (PerkinElmer).
Animal Studies and Non-Invasive in vivo Bioluminescent Imaging
Bioluminescent images were analyzed using tethered Living Image acquisition software (PerkinElmer). To produce BLI plots and associated graphs, total photon flux was calculated by drawing a region of interest across the thorax (experimental metastases) or head (tongue primary tumor growth) of each mouse individually in a supine position. This value was normalized to that obtained on the first day of scanning so that all mice began the experiment with an arbitrary starting BLI signal equal to 1.
Survival Analysis using Publically Available Microarray Datasets
NCBI GEO datasets GSE31056 (36) and GSE2379 (29) were downloaded as series matrix files of normalized expression values. Probe sets were matched to gene symbols for each platform. RNASeq (mRNA and miRNA) data from The Cancer Genome Atlas (TCGA) cohort of Head and Neck Cancer patients was downloaded as Level 3 data matrix files from the TCGA Data Portal available online (https://tcgadata.nci.nih.gov/tcga/). The BCGSC IlluminaHiSeq_miRNASeq (reads per million miRNA mapped) and the UNC IlluminaHiSeq_RNASeqV2 (normalized counts) data files were used for analysis. X-Tile software (73) was used to compute the optimal cutoff point for 2-population Kaplan-Meier analysis plotted using GraphPad Prism 6.
Copy number aberrations called using gene-or cancer-centric GISTIC analysis of TCGA datasets were obtained through the TCGA Copy Number Portal available online (http://www.broadinstitute.org/tcga/home; 74).
For whole cell lysates, cells were grown to 70% confluency, washed twice with PBS, and harvested in RIPA buffer (Thermo Scientific). For secreted protein analysis, 5x10 6 cells were seeded in 15 cm tissue culture places with 20ml serum-free FAD medium for 24 hours after which conditioned medium was harvested, filtered through a 0.45 μm syringe and concentrated using a 30 kDa Vivaspin 500 sample concentrator at full speed for 1 hour. Flow through was discarded and the remaining precipitate washed 3x for 30 minutes with 1M Tris-HCl (pH 8.0) followed by resuspension in RIPA buffer.
Protein lysates were sonicated for three 10-second cycles on medium power using a Biorupter (Diagenode) and sample concentration measured using a DC Protein Assay (Bio-Rad). 40 ug total protein per sample was separated on 4-12% polyacrylamide gradient gels, transferred to nitrocellulose membranes and detected using the following primary anti-human antibodies: LASP1 diluted 1:250 (Atlas HPA012072), NUAK1 diluted 1:250 (Atlas HPA027455), SPARC diluted 1:1,500
(Haemtech AON-5031), and GAPDH diluted 1:10,000 (Ambion AM4300). IRDye 800CW (800 nm channel) and 680LT (700 nm channel) secondary antibodies were used (LiCor). Western Blots were visualized using a Li-Cor Odyssey near infrared imager.
In vivo Intravasation
Total blood (w/heparin-lined syringe) was obtained by cardiac puncture under terminal anaesthesia from moribund mice that had received tongue xenografts of 10 
Multi-Photon Confocal Microscopy
To quantitatively investigate in vivo extravasation potential, 2. Immunohistochemistry FFPE specimens were de-waxed and rehydrated, using standard protocols, on the automated Leica ST5020. Antigen retrieval was done at 100°C in citrate buffer or
